Compound comparison · Research use only

CJC-1295 vs CJC-1295 DAC

CJC-1295 is a modified GRF(1-29), protease-resistant synthetic GHRH(1-29) analog (no albumin-binding DAC). CJC-1295 DAC is a synthetic 30-amino-acid GHRH(1-29) analog with Drug Affinity Complex (DAC) albumin-binding modification. They are different materials with different identities and different research literatures; the table below sets the two identities side by side, the sections after it summarise what each is studied for, and the certificate rows show how each has tested.

Identity

CJC-1295 and CJC-1295 DAC side by side

FieldCJC-1295CJC-1295 DAC
Catalogue nameCJC-1295CJC-1295 DAC
TypeSingle peptideSingle peptide
ClassModified GRF(1-29), protease-resistant synthetic GHRH(1-29) analog (no albumin-binding DAC)Synthetic 30-amino-acid GHRH(1-29) analog with Drug Affinity Complex (DAC) albumin-binding modification
ComponentsSingle compoundSingle compound
Molecular formulaC152H252N44O42C165H269N47O46
Molecular weight3367.97 Da3647.2 Da
Sequence length29 residues30 residues
CAS or identifier863288-34-0446262-90-4
Form suppliedLyophilized powderLyophilized powder
Sizes5mg5mg
Price from$45$60
Documented HPLC results4 (99.18 to 99.92%)3 (99.06 to 99.66%)
Testing laboratoriesAccurate Test Labs, Freedom DiagnosticsAccurate Test Labs, Freedom Diagnostics

Identity fields come from the catalogue entry for each compound. Certificate counts are documented third-party HPLC results with a published certificate; image-only documents are excluded from the counts.

Mechanisms

What the research literature describes

CJC-1295

  • GHRH Receptor Activation GHRH-R Agonist
  • Pulsatile GH Secretion Pulsatile GH
  • GH/IGF-1 Axis Response IGF-1 Axis

CJC-1295 DAC

  • GHRH Receptor Activation GHRH-R Agonist
  • Albumin Binding - Half-Life Extension DAC Technology
  • Downstream IGF-1 Elevation IGF-1 Axis
Research focus

What each is studied for

CJC-1295

  • Pulsatile GH Research Endocrinology
  • GHRH Analog Comparison Pharmacology
  • CJC / Ipamorelin Synergy Combination Research
  • GHRH Axis Models Animal Models

CJC-1295 DAC

  • Sustained GH Elevation GH / IGF-1 Axis
  • Albumin-Depot Mechanism Pharmacokinetics
  • GHRH Axis Selectivity Endocrinology
  • Growth Normalization Animal Models

Headings name the mechanisms and research applications described for each compound; the full text of each sits on the compound monograph linked below. They summarise findings reported in preclinical models. They describe what has been studied, not outcomes in people or animals outside the laboratory.

Go deeper

Catalogue, monographs and certificates

What is the difference between CJC-1295 and CJC-1295 DAC?

CJC-1295 is a modified GRF(1-29), protease-resistant synthetic GHRH(1-29) analog (no albumin-binding DAC); CJC-1295 DAC is a synthetic 30-amino-acid GHRH(1-29) analog with Drug Affinity Complex (DAC) albumin-binding modification. CJC-1295 has 29 residues and CJC-1295 DAC has 30. Their molecular identities, the models they have been studied in and their certificate records are all listed on this page.

Are CJC-1295 and CJC-1295 DAC sold together?

No. Eon Peptides lists them as separate catalogue items, each with its own sizes and its own certificates.

How has each tested?

CJC-1295: 4 documented third-party HPLC results from 99.18% to 99.92%. CJC-1295 DAC: 3 documented results from 99.06% to 99.66%. Every certificate is published and linked from each compound's lab results page.

Which one should a research project use?

That depends on the pathway and model under study, which is a scientific question this page does not answer. What it does is put the identities, the described mechanisms and the analytical records side by side so the choice can be made on documented facts. Both materials are for laboratory research use only.

For research use only. Not for human or veterinary use. Nothing on this page describes or recommends use in people or animals.